Vistagen Therapeutics (NASDAQ:VTGN) Stock Crosses Below 50-Day Moving Average - What's Next?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report)'s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.88 and traded as low as $2.62. Vistagen Therapeutics shares last traded at $2.65, with a volume of 121,644 shares changing hands.

Vistagen Therapeutics Stock Performance

The stock has a market cap of $78.50 million, a P/E ratio of -1.84 and a beta of 0.62. The stock has a 50-day moving average price of $2.87 and a 200-day moving average price of $2.91.

Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.02. The firm had revenue of $230 billion for the quarter, compared to analysts' expectations of $0.18 million. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. Sell-side analysts forecast that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vistagen Therapeutics

Institutional investors have recently modified their holdings of the company. Valence8 US LP purchased a new stake in shares of Vistagen Therapeutics in the 3rd quarter valued at $103,000. HighTower Advisors LLC purchased a new position in shares of Vistagen Therapeutics in the third quarter worth about $64,000. Jane Street Group LLC bought a new stake in shares of Vistagen Therapeutics in the 3rd quarter valued at about $59,000. Virtu Financial LLC lifted its stake in shares of Vistagen Therapeutics by 30.5% in the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company's stock valued at $61,000 after acquiring an additional 4,722 shares during the last quarter. Finally, R Squared Ltd bought a new position in Vistagen Therapeutics during the 4th quarter worth approximately $25,000. 78.39% of the stock is currently owned by institutional investors.

Remove Ads

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.